← Medical · Causes of death · how systems treat it
Metabolic / renal · Master rank #9 · ~3.2% of deaths (Top 20 avg)
Short comparison of all 20 systems on one page. Click a country for the full treatment / prevention / lifestyle page.
High-tech acute care; prior auth; huge price variation by payer. Primary-care chronic-disease packages + newer cardio-renal drugs. High obesity/diabetes; GLP-1 boom with insurance fights
Public clusters for most serious care; private ISP for those who pay up. Primary-care chronic-disease packages + newer cardio-renal drugs. War on Diabetes public campaign + MediSave for chronic care
High ambulatory volume; global budgets constrain growth. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via NHI single payer.
Fund-integrated care; strong tech/trauma capacity. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via Mandatory health funds.
Strong primary care gatekeeping with private hospital overflow. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via Universal Medicare + private optional.
Insurer-organized pathways; low uninsured rate. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via Mandatory private insurance, regulated.
GP gatekeeping, NICE pathways, waiting-list rationing for elective care. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via NHS tax-funded.
Primary-care centered; strong public health infrastructure. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via Decentralized tax-funded.
Wealthy Nordic model; GP lists + municipal prevention. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via Tax-funded national system.
Pharmac constrains drug spend; public hospitals for major care. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via Tax-funded + private optional.
Ambulatory specialist access; strong pharma/device availability. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via Statutory health insurance.
High spend, high access, canton variation. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via Mandatory private insurance.
Municipal prevention + regional hospitals. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via Tax-funded.
Single-payer core with wait times; limited private parallel. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via Single payer (provincial).
Strong primary care; Mediterranean public-health framing. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via SNS tax-funded.
Ambulatory specialists + hospital sector; dense capacity. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via Statutory sickness funds.
Public primary care + occupational health overlay. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via Tax-funded / reforming.
GP gatekeeping; north/south performance gaps. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via SSN tax-funded.
Very high utilization; hospital-heavy; aggressive screening culture. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via NHI single payer + private hospitals.
High visit frequency, low unit prices, specialist access without US-style referral walls. Primary-care chronic-disease packages + newer cardio-renal drugs. Metabolic / renal pathway via Statutory insurance, fee schedule.